CADILLAC

PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMIZESTRANT PLUS RIBOCICLIB IN PATIENTS WITH HORMONE RECEPTOR POSITIVE (HR+) BREAST CANCER. THE CADILLAC STUDY EVALUATES, IN PATIENTS WITH ADVANCED HR+/HER2- BREAST CANCER WHO HAVE STOPPED RESPONDING TO STANDARD TREATMENTS, THE EFFICACY AND SAFETY OF THE COMBINATION OF CAMIZESTRANT (A NOVEL SELECTIVE ESTROGEN RECEPTOR DEGRADER) TOGETHER WITH THE CDK4/6 INHIBITOR RIBOCICLIB, USING AN EXTERNAL CONTROL ARM OF PATIENTS PREVIOUSLY TREATED WITH ENDOCRINE THERAPY PLUS RIBOCICLIB AS STANDARD OF CARE.